Fertility and sterility · 2026
Oocyte Cryopreservation Before and During Puberty: Experimental to Emerging Practice.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salama Mahmoud, Gomez-Lobo Veronica, Gracia Clarisa, Woodruff Teresa K
Аннотация
OBJECTIVE: To evaluate the published clinical data on oocyte cryopreservation as an option for preserving the reproductive potential of females before and during puberty, while addressing the research gaps, recent advancements and future directions in the field.
DESIGN: Narrative review SUBJECTS: Not applicable.
INTERVENTION (FOR RCT) OR EXPOSURE (FOR OBSERVATIONAL STUDIES): Not applicable.
MAIN OUTCOME MEASURES: Not applicable.
RESULTS: Oocyte cryopreservation to preserve the reproductive potential in various benign and malignant conditions can be obtained through controlled ovarian stimulation (with cryopreservation of mature oocytes or in-vitro-maturation of immature oocytes) or in-vitro maturation at the time of ovarian tissue cryopreservation. These techniques have different levels of clinical maturity and evidence of success. Published clinical data, though limited, supports the feasibility of oocyte cryopreservation through these varying techniques before and during puberty and especially after menarche. The reproductive potential of these oocytes including the risk for aneuploidy, however, has not been evaluated and uncertainties regarding potential long-term effects of ovarian stimulation and the psychosocial impact in young populations remain. As the utilization of oocyte cryopreservation before and during puberty continues to expand, long-term follow-up studies will be essential to define both safety and reproductive effectiveness. The future of fertility preservation for girls before and during puberty will not be defined by any single clinical innovation such as oocyte cryopreservation but also the convergence of advances across eIVFG, artificial ovary engineering, neoadjuvant fertoprotective pharmacology targeting the CHEK2-Tap63a axis and complementary DNA damage response pathways, and broader emerging biotechnologies which are described here.
CONCLUSION: Despite limitations, published data support the feasibility of oocyte cryopreservation before and during puberty in various benign and malignant conditions. However, long-term follow-up studies are required to define safety and reproductive effectiveness.
DESIGN: Narrative review SUBJECTS: Not applicable.
INTERVENTION (FOR RCT) OR EXPOSURE (FOR OBSERVATIONAL STUDIES): Not applicable.
MAIN OUTCOME MEASURES: Not applicable.
RESULTS: Oocyte cryopreservation to preserve the reproductive potential in various benign and malignant conditions can be obtained through controlled ovarian stimulation (with cryopreservation of mature oocytes or in-vitro-maturation of immature oocytes) or in-vitro maturation at the time of ovarian tissue cryopreservation. These techniques have different levels of clinical maturity and evidence of success. Published clinical data, though limited, supports the feasibility of oocyte cryopreservation through these varying techniques before and during puberty and especially after menarche. The reproductive potential of these oocytes including the risk for aneuploidy, however, has not been evaluated and uncertainties regarding potential long-term effects of ovarian stimulation and the psychosocial impact in young populations remain. As the utilization of oocyte cryopreservation before and during puberty continues to expand, long-term follow-up studies will be essential to define both safety and reproductive effectiveness. The future of fertility preservation for girls before and during puberty will not be defined by any single clinical innovation such as oocyte cryopreservation but also the convergence of advances across eIVFG, artificial ovary engineering, neoadjuvant fertoprotective pharmacology targeting the CHEK2-Tap63a axis and complementary DNA damage response pathways, and broader emerging biotechnologies which are described here.
CONCLUSION: Despite limitations, published data support the feasibility of oocyte cryopreservation before and during puberty in various benign and malignant conditions. However, long-term follow-up studies are required to define safety and reproductive effectiveness.